• How ATPγS Signals Through P2Y Receptors

  2026-10-20

  ATPγS tetralithium salt is described as an ATP analogue that activates the P2Y2 and P2Y11 purinergic receptor subtypes. Its documented effects span receptor pharmacology, cellular calcium influx, prostaglandin E2 production, and norepinephrine uptake. These readouts represent different levels of biology, so their reported potency values should not be treated as interchangeable. The available evidence supports a conceptual model of P2Y-linked signaling, while leaving important boundaries around receptor selectivity, assay context, and transferability between cell systems.

• H-89: Evidence-Bounded PKA Inhibitor Overview

  2026-10-19

  H-89 is marketed by APExBIO as a cAMP-dependent protein kinase inhibitor for probing PKA-linked signaling. The product page reports an IC50 of 48 nM and weak activity against PKG and casein kinase, but no identity-matched research paper, assay dataset, cellular outcome, or independent selectivity analysis is available here. Accordingly, H-89 is best interpreted as a pharmacological perturbation tool whose results require separation of PKA-dependent effects from broader kinase or assay-context effects.

• Cy3 Maleimide: Identity, Mechanism, and Evidence

  2026-10-18

  Cy3 maleimide (non-sulfonated) is a supplier-described thiol-reactive fluorescent labeling reagent. APExBIO reports covalent attachment through a maleimide group, excitation and emission maxima of 555 and 570 nm, an extinction coefficient of 150,000 M⁻¹cm⁻¹, and a quantum yield of 0.31. These properties define a measurement tool for labeled biomolecules, not evidence of a biological interaction, repair mechanism, or cellular function. No identity-matched research evidence is available in the materials reviewed.

• Cy3 Maleimide: Identity, Mechanism and Evidence Limits

  2026-10-17

  APExBIO describes non-sulfonated Cy3 maleimide as a thiol-reactive fluorescent labeling reagent for cysteine-containing biomolecules and thiol-modified oligonucleotides. Its stated spectral properties support interpretation as a fluorescence probe, but the available record contains no identity-matched research paper, independent validation, outcome statistics, or direct comparison with alternative dyes. The product information therefore supports a conceptual labeling and measurement framework, not claims about biological performance, cellular uptake, or assay selectivity.

• Rubropunctamine: Identity, Claims, and Evidence Limits

  2026-10-16

  Rubropunctamine is described by APExBIO as a red erythrocyanine pigment with antimicrobial activity against bacteria, some yeasts, and filamentous fungi. The available product information does not establish a molecular target, mode of action, assay readout, quantitative potency, or identity-matched research outcome. Its reported embryotoxic and teratogenic potential is likewise presented without model, endpoint, or exposure data, so the compound is best treated as a research subject with substantial evidence and applicability boundaries.

• Cy3 NHS Ester: Identity, Mechanism and Evidence

  2026-10-16

  A source-bounded overview of Cy3 NHS ester (non-sulfonated), covering its documented chemical identity, amine-labeling mechanism, fluorescence readout, formulation boundaries, and the limited evidence available for product-specific claims.

• When Context Changes a Cytoskeletal Result

  2026-10-15

  The same reduction in intracellular bacterial signal can represent impaired entry, altered trafficking, reduced replication, or cellular injury. In the Drosophila S2-cell study of Spiroplasma eriocheiris, Cytochalasin B supported a role for actin-dependent processes, but the model and pharmacological readouts limit how specifically that result can be interpreted.

• Single Firefly Luciferase Kit: Evidence Boundaries

  2026-10-15

  APExBIO identifies K2236 as a Single Firefly Luciferase Reporter Gene Assay Kit, but the available product information does not provide an identity-matched research paper, detailed formulation, validation data, or comparative performance evidence. The product name supports a limited, class-level interpretation of luminescence as a downstream reporter signal; it does not establish product-specific performance or biological conclusions.

• DiR: What Its Fluorescent Signal Can Establish

  2026-10-14

  DiR, also called DiIC 18 (7), is described by APExBIO as a lipophilic, near-infrared membrane-labeling probe for cell, tissue, neuronal, and particle-tracking applications. The available evidence supports a measurement interpretation centered on dye-associated membrane fluorescence, but it does not independently establish labeling performance, cytotoxicity, persistence, vesicle integrity, or biological function.

• Norovirus, NINJ1 and Selective NS1 Secretion

  2026-10-14

  Song et al. report that murine norovirus uses the host membrane-rupture factor NINJ1 and caspase-3 to release the viral protein NS1 through an unconventional, partly selective secretion pathway. The findings are mechanistically substantial but remain bounded by their reliance on murine virus strains and mouse models.

• Mitochondrial Repair in Diabetic Periodontitis

  2026-10-13

  Xie and colleagues investigate whether a hierarchically targeted, ROS-responsive nanoparticle–hydrogel platform can interrupt the mitochondrial oxidative-stress loop that sustains inflammation in diabetic periodontitis. Their in vitro and rat-model findings support a preclinical proof of concept, but the supplied report does not establish clinical efficacy, long-term safety, or the independent contribution of each platform component.

• Azilsartan and Reactive Astrocyte Signaling

  2026-10-13

  A 2024 cell-based study examined whether gastrodin alters renin–angiotensin system and SIRT3-associated responses in astrocytes exposed to microglia-derived signals. Azilsartan was used as an AT1-directed pharmacological probe, but the findings remain limited to an in vitro model and do not establish clinical benefit or therapeutic efficacy.

• HyperScribe T7 Cy3 RNA Labeling: Evidence Scope

  2026-10-12

  The HyperScribe™ T7 High Yield Cy3 RNA Labeling Kit Plus is documented by the supplier as a research-use in vitro transcription kit for producing randomly Cy3-modified RNA probes. In the absence of a matched peer-reviewed paper, its stated yield, efficiency, and application suitability remain manufacturer claims rather than independently verified findings.

• DiR, EV Tracking, and Evidence Boundaries

  2026-10-12

  DiR (DiIC 18 (7)) is a near-infrared membrane-labeling probe with potential relevance to visualizing labeled cells, tissues, or vesicular material. However, the supplied 2024 extracellular-vesicle study evaluates mononuclear phagocyte system distribution and CD47-mediated immune evasion without documenting DiR use. Its findings therefore support a conceptual distinction between tracking fluorescence and demonstrating therapeutic EV identity, persistence, or function.

• SUMO Protease (Ulp): Evidence and Scope

  2026-10-11

  APExBIO product K1103 is described as a recombinant Ulp1-derived cysteine protease intended for conceptual removal of compatible SUMO fusion tags. The available evidence is limited to supplier documentation; no matched peer-reviewed paper or independent performance dataset was provided.

8088 records 1/540 page Next 12345 下5页 Last page